Parkinson Disease Treatment

FDA OKs New Wearable Treatment for Parkinson's Disease

The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced Parkinson's disease, Supernus Pharmaceuticals announced on Tuesday. The wearable device is the first subcutaneous apomorphine infusion device for Parkinson's and provides continuous treatment during the day, Supernus noted.

The New York Times · 3d

The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other conditions with newer weight-loss drugs.

Becker's Hospital Review · 2d

GLP-1 drug fails to slow Parkinson's: Study

A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The Lancet,

Ozempic-Type Drug Fails To Slow Parkinson’s, Study Finds

WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's ...

Knowridge6h

A new wearable treatment for Parkinson’s motor fluctuations

The U.S. Food and Drug Administration (FDA) has approved Onapgo (apomorphine hydrochloride) injection, the first and only ...

U.S. FDA approves Supernus' drug-device combination for Parkinson's disease

The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat ...

1don MSN

Diabetes drug similar to Ozempic showed no benefits for patients with Parkinson’s disease

A drug for treating diabetes similar to popular weight-loss medicines such as Ozempic did not show any benefits for people ...

Pharm Exec10h

FDA Approves Supernus Pharmaceuticals’ Onapgo for Managing Motor Fluctuations in Parkinson Disease

Approval of Onapgo (apomorphine hydrochloride) marks the first and only subcutaneous apomorphine infusion device for managing ...

FDA approves wearable infusion device for advanced Parkinson disease

The U.S. Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only ...

15hon MSN

Red flags of Parkinson's disease as mum is diagnosed at just 28 years old

Nicole LaBolle initially dismissed her shaking as something fairly common before facing a Parkinson's diagnosis at 28 ...

MedPage Today1d

Why Did a GLP-1 Receptor Agonist Fail This Parkinson's Trial?

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Rolling Out8d

A breakthrough in Parkinson’s disease detection

AI-powered blood test detects Parkinson's disease years before symptoms appear, revolutionizing early diagnosis and treatment ...

Healio2d

GLP-1 does not slow Parkinson’s disease progression in phase 3 study

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

Samsung recognizes Española Valley High School for innovative Parkinson’s Disease project

Samsung is recognizing Española Valley High School for its student’s efforts to help people dealing with Parkinson’s Disease. Students, in coordination with ...

New Atlas2d

US approves "milestone" Parkinson's treatment for 2025 release

Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results